## Adverse Effects and Contraindications of Combined Oral Contraceptive Pills ### Understanding the "EXCEPT" Question **Key Point:** This question asks which statement is NOT an established adverse effect or contraindication of COCPs. Option D describes a **benefit** (decreased cancer risk), not an adverse effect — making it the correct "EXCEPT" answer. ### Cardiovascular Risks (Established Adverse Effects) | Risk | Evidence | Mechanism | |------|----------|-----------| | **VTE (DVT/PE)** | 3–4× increased risk | Estrogen increases factors II, VII, X; decreases antithrombin III; third-generation progestins (desogestrel, gestodene) carry higher VTE risk than second-generation (levonorgestrel) | | **Myocardial Infarction** | Increased in smokers >35 years | Estrogen + smoking → endothelial dysfunction, platelet aggregation, thrombosis (WHO Category 4 contraindication) | | **Stroke** | Rare; increased with migraine with aura | Estrogen + migraine aura = WHO Category 4 (absolute contraindication) | ### Cancer Associations with COCPs **High-Yield:** COCPs have **opposite effects** on different cancers: | Cancer Type | Effect | Evidence | |-------------|--------|----------| | **Cervical** | **INCREASED** | Relative risk 1.5–2.0 with >5 years use; risk persists for several years after stopping but does eventually return toward baseline over 5–10 years | | **Ovarian** | **DECREASED** | 40–50% risk reduction; protective effect continues after discontinuation | | **Endometrial** | **DECREASED** | ~50% risk reduction; protective effect continues after discontinuation | | **Breast** | Slightly increased during use | Risk returns to baseline within ~10 years of stopping | ### Why Option D Is the EXCEPT Answer **Clinical Pearl:** The question asks for adverse effects and contraindications. Option D — decreased risk of ovarian and endometrial cancer — is a well-established **protective benefit** of COCPs, not an adverse effect. This is supported by decades of epidemiological data (WHO, IARC, and multiple cohort studies cited in Harrison's Principles of Internal Medicine). A benefit cannot be an "adverse effect," making D the correct EXCEPT answer. ### Why Options A, B, C Are Established Associations 1. **Option A (VTE)** — Established adverse effect. Third-generation progestins confer higher VTE risk; thrombophilia (e.g., Factor V Leiden) compounds this risk significantly. ✓ 2. **Option B (MI in smokers >35)** — Established contraindication (WHO MEC Category 4). Smoking >15 cigarettes/day + age >35 + COCPs = unacceptable cardiovascular risk. ✓ 3. **Option C (Cervical cancer)** — Established association. IARC and WHO classify COCPs as Group 1 carcinogens for cervical cancer with prolonged use. The risk does persist for years after discontinuation but eventually returns toward baseline. The statement in Option C is broadly consistent with established evidence. ✓ **High-Yield:** For NEET PG, remember COCPs **decrease** ovarian and endometrial cancer risk (protective) but **increase** cervical cancer risk (adverse). The protective effects on ovarian/endometrial cancer are among the most tested non-contraceptive benefits of COCPs (KD Tripathi, Essentials of Medical Pharmacology; Dutta's Textbook of Gynecology).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.